Citigroup, Deutsche Bank and SMBC have signed Teva Pharmaceuticals' $350m loan, which was increased from $150m following an oversubscription.
The deal comprises a $175m three year tranche paying 45bp over Libor and a $175m five year tranche paying Libor plus 55bp.
The other participants
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: email@example.com or find out more online here.